Articles with "maturation antigen" as a keyword



Photo by artlasovsky from unsplash

CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status

Sign Up to like & get
recommendations!
Published in 2022 at "American Journal of Hematology"

DOI: 10.1002/ajh.26583

Abstract: In this open‐label, single‐arm, phase I/II clinical trial, we evaluated the efficacy of anti‐B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)‐T cell (HDS269B) therapy in 49 relapsed/refractory multiple myeloma (RRMM) patients, including 20 with… read more here.

Keywords: cell; therapy; car; maturation antigen ... See more keywords
Photo from wikipedia

B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives

Sign Up to like & get
recommendations!
Published in 2020 at "International Journal of Cancer"

DOI: 10.1002/ijc.33002

Abstract: Despite major advances in the treatment of multiple myeloma (MM), it remains a largely incurable disease with long‐term control often dependent on continuous therapy. More effective, better tolerated treatments are therefore required to achieve durable… read more here.

Keywords: maturation antigen; multiple myeloma; antigen; cell maturation ... See more keywords
Photo from wikipedia

An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

Sign Up to like & get
recommendations!
Published in 2021 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2021.1872540

Abstract: ABSTRACT Introduction: B-cell maturation antigen (BCMA) targeted therapy (BCMA-TT) has emerged as a promising treatment for Multiple Myeloma (MM). the three most common treatment modalities for targeting BCMA are antibody-drug conjugates (ADCs), bispecific antibody constructs,… read more here.

Keywords: maturation antigen; antibody; multiple myeloma; antigen ... See more keywords
Photo from wikipedia

Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment

Sign Up to like & get
recommendations!
Published in 2020 at "British Journal of Haematology"

DOI: 10.1111/bjh.16752

Abstract: Serum B‐cell maturation antigen (sBCMA) is a novel biomarker for B‐cell malignancies. A normal reference range ( read more here.

Keywords: maturation antigen; serum cell; treatment; cell maturation ... See more keywords
Photo from wikipedia

Gene therapy with B‐cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma

Sign Up to like & get
recommendations!
Published in 2022 at "British Journal of Haematology"

DOI: 10.1111/bjh.18230

Abstract: The delivery of bispecific antibodies (BsAbs) targeting B‐cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study,… read more here.

Keywords: cell maturation; cd3; maturation antigen; gene therapy ... See more keywords
Photo from wikipedia

Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review

Sign Up to like & get
recommendations!
Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-131849

Abstract: Introduction Multiple Myeloma (MM) is a plasma cell dyscrasia characterized by neoplastic proliferation of plasma cells. Despite the recent advances in disease management, it still contributes to significant morbidity and mortality, thus highlighting the unmet… read more here.

Keywords: maturation antigen; myeloma; bcma; multiple myeloma ... See more keywords
Photo from wikipedia

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

Sign Up to like & get
recommendations!
Published in 2018 at "Frontiers in Immunology"

DOI: 10.3389/fimmu.2018.01821

Abstract: The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM).… read more here.

Keywords: maturation antigen; bcma; multiple myeloma; antigen ... See more keywords